JP2016532647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016532647A5 JP2016532647A5 JP2016520627A JP2016520627A JP2016532647A5 JP 2016532647 A5 JP2016532647 A5 JP 2016532647A5 JP 2016520627 A JP2016520627 A JP 2016520627A JP 2016520627 A JP2016520627 A JP 2016520627A JP 2016532647 A5 JP2016532647 A5 JP 2016532647A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- methyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888822P | 2013-10-09 | 2013-10-09 | |
| US61/888,822 | 2013-10-09 | ||
| PCT/IB2014/064836 WO2015052610A1 (en) | 2013-10-09 | 2014-09-25 | Antagonists of prostaglandin ep3 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016532647A JP2016532647A (ja) | 2016-10-20 |
| JP2016532647A5 true JP2016532647A5 (enExample) | 2017-10-26 |
| JP6348582B2 JP6348582B2 (ja) | 2018-06-27 |
Family
ID=51900918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520627A Expired - Fee Related JP6348582B2 (ja) | 2013-10-09 | 2014-09-25 | プロスタグランジンｅｐ３受容体の拮抗薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9278953B2 (enExample) |
| EP (1) | EP3055300B1 (enExample) |
| JP (1) | JP6348582B2 (enExample) |
| AR (1) | AR097963A1 (enExample) |
| CA (1) | CA2926568C (enExample) |
| ES (1) | ES2665153T3 (enExample) |
| TW (1) | TW201527297A (enExample) |
| UY (1) | UY35776A (enExample) |
| WO (1) | WO2015052610A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3237401B1 (en) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
| US10590083B2 (en) | 2017-08-10 | 2020-03-17 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists |
| US10399944B2 (en) | 2017-08-10 | 2019-09-03 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists |
| US10336701B2 (en) * | 2017-08-10 | 2019-07-02 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists |
| BR112020021612A2 (pt) | 2018-05-17 | 2021-01-26 | Bayer Aktiengesellschaft | derivados substituídos de di-hidropirazolo pirazina carboxamida |
| WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
| WO2022215072A2 (en) | 2021-04-07 | 2022-10-13 | Hadasit Medical Research Services & Development Ltd. | Therapeutic modalities for inhibiting pancreatic beta cell impairment and treating diabetes |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| PT1094816E (pt) | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| GEP20053710B (en) | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| EP1753748B1 (en) | 2004-05-12 | 2009-07-29 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
| EA010888B1 (ru) | 2004-05-25 | 2008-12-30 | Пфайзер Продактс, Инк. | Тетраазабензо[е]азуленовые производные и их аналоги |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2007027630A2 (en) | 2005-08-30 | 2007-03-08 | Smithkline Beecham Corporation | Genes associated with type ii diabetes mellitus |
| EP2463283B1 (en) | 2006-04-20 | 2014-06-11 | Pfizer Products Inc. | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| EP2097420B1 (en) | 2006-11-29 | 2012-04-04 | Pfizer Products Inc. | Spiroketone inhibitors of acetyl-coa carboxylase |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| WO2009144554A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| CA2724603A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| MX2011002166A (es) | 2008-08-28 | 2011-04-07 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol. |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| ES2427279T3 (es) | 2009-03-11 | 2013-10-29 | Pfizer Inc. | Derivados de benzofuranilo usados como inhibidores de glucocinasa |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| JP2012526097A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| KR20120061063A (ko) | 2009-06-05 | 2012-06-12 | 화이자 인코포레이티드 | Ｇｐｒ 119 조절제로서의 ｌ-(피페리딘-4-일)-피라졸 유도체 |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
-
2014
- 2014-09-25 JP JP2016520627A patent/JP6348582B2/ja not_active Expired - Fee Related
- 2014-09-25 ES ES14799209.3T patent/ES2665153T3/es active Active
- 2014-09-25 EP EP14799209.3A patent/EP3055300B1/en not_active Not-in-force
- 2014-09-25 CA CA2926568A patent/CA2926568C/en not_active Expired - Fee Related
- 2014-09-25 WO PCT/IB2014/064836 patent/WO2015052610A1/en not_active Ceased
- 2014-10-06 TW TW103134754A patent/TW201527297A/zh unknown
- 2014-10-06 US US14/506,752 patent/US9278953B2/en not_active Expired - Fee Related
- 2014-10-08 AR ARP140103751A patent/AR097963A1/es unknown
- 2014-10-08 UY UY0001035776A patent/UY35776A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017071634A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2016523270A5 (enExample) | ||
| CY1119487T1 (el) | Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα | |
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| WO2016205475A3 (en) | Tgr5 modulators and methods of use thereof | |
| JP2016505010A5 (enExample) | ||
| MA44873A (fr) | Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative | |
| JP2017517512A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| PE20211548A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| TR201904658T4 (tr) | Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları. | |
| JP2013502431A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| JP2016505637A5 (enExample) | ||
| EP4011871A3 (en) | Processes for preparing oxathiazin-like compounds | |
| JP2015504909A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2016540749A5 (enExample) | ||
| JP2016540803A5 (enExample) |